Hydralazine-induced liver injury: a review and discussion.
BMJ Case Rep
; 14(8)2021 Aug 17.
Article
in English
| MEDLINE | ID: covidwho-1361973
ABSTRACT
Hydralazine is a commonly prescribed antihypertensive agent. Some of its labelled adverse reactions include lupus-like syndrome, tachycardia, headache and fever. Despite its well-known side effects, little is known about hydralazine's hepatotoxic effects. We report the case of a 54-year-old female patient who was started on hydralazine for hypertension management but later presented with hydralazine-induced liver injury. Her initial presentation consisted of non-specific symptoms and a hepatocellular injury pattern. Liver biopsy revealed hepatic steatosis. Three weeks after discontinuation of hydralazine, the patient's liver enzymes normalised, and her symptoms resolved. Few studies have examined the incidence and mechanism by which hydralazine induces a liver injury pattern. With this case, we review the literature, the pathogenesis involved and the eventual management of hydralazine-induced liver injury. We propose close monitoring of liver enzymes for patients on hydralazine throughout their treatment course.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Chemical and Drug Induced Liver Injury
/
Chemical and Drug Induced Liver Injury, Chronic
/
Hypertension
Type of study:
Case report
/
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2021-243278
Similar
MEDLINE
...
LILACS
LIS